BAX and DDB2 as biomarkers for acute radiation exposure in the human blood ex vivo and non-human primate models.

Autor: Kanagaraj K; Center for Radiological Research, Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA. kk3581@cumc.columbia.edu., Phillippi MA; Center for Radiological Research, Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA., Ober EH; Center for Radiological Research, Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA., Shuryak I; Center for Radiological Research, Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA., Kleiman NJ; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA., Olson J; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Schaaf G; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Cline JM; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Turner HC; Center for Radiological Research, Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA. ht2231@cumc.columbia.edu.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Aug 20; Vol. 14 (1), pp. 19345. Date of Electronic Publication: 2024 Aug 20.
DOI: 10.1038/s41598-024-69852-z
Abstrakt: There are currently no available FDA-cleared biodosimetry tools for rapid and accurate assessment of absorbed radiation dose following a radiation/nuclear incident. Previously we developed a protein biomarker-based FAST-DOSE bioassay system for biodosimetry. The aim of this study was to integrate an ELISA platform with two high-performing FAST-DOSE biomarkers, BAX and DDB2, and to construct machine learning models that employ a multiparametric biomarker strategy for enhancing the accuracy of exposure classification and radiation dose prediction. The bioassay showed 97.92% and 96% accuracy in classifying samples in human and non-human primate (NHP) blood samples exposed ex vivo to 0-5 Gy X-rays, respectively up to 48 h after exposure, and an adequate correlation between reconstructed and actual dose in the human samples (R 2  = 0.79, RMSE = 0.80 Gy, and MAE = 0.63 Gy) and NHP (R 2  = 0.80, RMSE = 0.78 Gy, and MAE = 0.61 Gy). Biomarker measurements in vivo from four NHPs exposed to a single 2.5 Gy total body dose showed a persistent upregulation in blood samples collected on days 2 and 5 after irradiation. The data indicates that using a combined approach of targeted proteins can increase bioassay sensitivity and provide a more accurate dose prediction.
(© 2024. The Author(s).)
Databáze: MEDLINE